Liposphere’s patented knee joint
articulation injectable under development
CCoat® is designed for use in patients with mild to moderate knee osteoarthritis to reduce pain and improve mobility. Acting through a purely physical mechanism of action demonstrated in pre-clinical testing, it forms a lubricating coating at the cartilage interface to support ease of joint movement under non-clinical conditions.
This function is achieved by utilizing lipid-based spherical structures, which retain and organize surrounding water, and together with their three-dimensional morphology, contribute to the formation of a highly hydrated lipid-based interface during joint articulation that has been shown in laboratory tests to enable physical lubrication.
Disclaimer: CCoat® is currently in development and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). It is not available for commercial sale or clinical use in the United States.
Clinical
First-In-Human trials
demonstrated that CCoat is safe, reduces knee pain for up to
6 months and leads to improved functionality of the knee joint.
Quick Pain Relief and Improved Functionality
In a clinical study, CCoat has demonstrated rapid and sustained within-group clinical improvements for people suffering from mild-to-moderate knee osteoarthritis across key clinical parameters, including pain, mobility, physical activity, and quality of life. Clinical data have shown an onset of pain relief starting as early as 7 days post-injection, with improvements observed up to 26 weeks (6 months). Using the KOOS scoring system (Knee injury and Osteoarthritis Outcome Score), patients reported that after being treated with a single CCoat injection they were able to move better, feel better, and return to activities they had previously struggled with, due to pain reduction during these activities. These within-group improvements were supported by statistically significant results.
[Note: These clinical outcomes are derived from one clinical study with a limited sample size of 46 patients treated with CCoat vs 48 patients treated with placebo (saline).]
Safe and Innovative Technology
CCoat is a nonpyrogenic product, which is water-based and highly biocompatible. Regulated as a medical device in the EU, it does not contain any active ingredients or medicinal substances; its effect is achieved strictly through its physical properties. Clinical data indicate a favorable safety profile with no device-related serious adverse events reported. The occurrence of mild, transient events, such as minimal joint swelling and injection site pain, was infrequent and comparable to established state-of-the-art standards for intra-articular knee injections.
[Note:These clinical outcomes are derived from one clinical study with a limited sample size of 46 patients treated with CCoat vs. 48 patients treated with placebo (saline).]
MARKET RELEVANCE
The market standard non-surgical treatments are only partially meeting the needs of knee OA sufferers.
…which means that CCoat as an effective, structural boundary lubricant has the potential to capture significant share in the multi-billion dollar markets of human orthopaedics, sports injuries and pets.
Scaling up and growth
Clear path to growth and
significant valuation upside
Liposphere is currently raising Series B capital to accelerate CCoat® development and access the European market.
Only EU
Only Human Knee OA
And Elite Sports
Contact us
Call us or send a message using the contact form.
We look forward to hearing from you.
E-Mail: contact@lipo-sphere.com